drugset / Trial / NCT06666283
A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients
RandomizedSequentialQuadruple-blindTreatment
Summary
The study will be a single center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, PK and PD of AP303 following 2-week oral administration to Diabetic Kidney Disease patients.
Timeline
- Start
- 2025-02-27
- Primary completion
- 2025-09-25
- Completion
- 2025-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AP303 | Unknown | 150 ug | Oral |